Quantum Biopharma Files Routine 6-K Report on March 26, 2026
Ticker: QNTM · Form: 6-K · Filed: Mar 26, 2026 · CIK: 0001771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, procedural-update
TL;DR
**Quantum Biopharma's 6-K is a routine foreign issuer report, no new news here.**
AI Summary
Quantum Biopharma Ltd. filed a 6-K on March 26, 2026, indicating a routine report for a foreign issuer. This filing, with accession number 0001171843-26-001926, includes the 6-K form and a press release (EX-99.1). For investors, this filing itself doesn't contain new material financial or operational news, but rather serves as a procedural update, meaning there's no immediate impact on the stock based solely on this filing's content.
Why It Matters
This filing is a standard procedural report for foreign companies and does not contain specific new financial or operational information that would directly impact the stock price.
Risk Assessment
Risk Level: low — The filing is purely administrative and does not disclose any new risks or material changes to the company's operations or financials.
Analyst Insight
Investors should note that this 6-K is a standard procedural filing and does not contain new material information. Therefore, no immediate investment action is warranted based solely on this report; further research into the company's actual press releases or other filings would be necessary for actionable insights.
Key Numbers
- 6009 — Size of FORM 6-K document (indicates the size in bytes of the main 6-K document)
- 8135 — Size of EX-99.1 (Press Release) document (indicates the size in bytes of the accompanying press release)
Key Players & Entities
- Quantum Biopharma Ltd. (company) — the filer of the 6-K report
- 0001771885 (company) — the CIK of Quantum Biopharma Ltd.
- 0001171843-26-001926 (other) — the SEC Accession No. for this filing
- 2026-03-26 (date) — the filing date and period of report
Forward-Looking Statements
- Quantum Biopharma Ltd. will continue to file routine 6-K reports as required for foreign issuers. (Quantum Biopharma Ltd.) — high confidence, target: Ongoing
FAQ
What is the purpose of a 6-K filing for Quantum Biopharma Ltd.?
A 6-K filing, as indicated by the title 'Report of foreign issuer [Rules 13a-16 and 15d-16]', is a report used by foreign private issuers to furnish the SEC with material information that is made public in their home country, distributed to shareholders, or filed with a foreign exchange.
When was this specific 6-K filing submitted and accepted by the SEC?
This 6-K filing (Accession No. 0001171843-26-001926) was filed on 2026-03-26 and accepted on 2026-03-26 at 08:00:10.
What documents are included in this 6-K submission?
The submission includes two documents: 'FORM 6-K f6k_032626.htm' which is the 6-K form itself, and 'PRESS RELEASE exh_991.htm' which is Exhibit 99.1.
What is the business address of Quantum Biopharma Ltd. as stated in the filing?
The business address for Quantum Biopharma Ltd. is 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7.
What is Quantum Biopharma Ltd.'s SIC code and what industry does it represent?
Quantum Biopharma Ltd.'s SIC code is 2834, which represents 'Pharmaceutical Preparations', indicating they operate in the pharmaceutical industry.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2026-03-26 08:00:10
Filing Documents
- f6k_032626.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-26-001926.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: March 26, 2026 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated March 26, 2026